Zepbound® is the brand name for tirzepatide, an FDA-approved injectable medication for chronic weight management in adults. Made by Eli Lilly and Company, it arrived on the U.S. market in November 2023 for obesity and received a second FDA approval in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, making it the first and only weight-loss medication with an FDA-approved OSA indication. At Midwest Mind & Body Healthcare, we prescribe Zepbound to qualifying adults in Omaha, the surrounding metro, and 16 states via telehealth.
What sets tirzepatide apart from semaglutide (Wegovy, Ozempic) is its mechanism. Tirzepatide is a dual agonist: it activates both the GIP receptor and the GLP-1 receptor. Semaglutide activates only the GLP-1 receptor. GIP (glucose-dependent insulinotropic polypeptide) is a second incretin hormone that appears to complement GLP-1 activity on appetite regulation, insulin secretion, and fat metabolism. The practical result in clinical trials has been numerically higher average weight loss and, in head-to-head diabetes data (SURPASS-2), superior glycemic outcomes versus semaglutide. Tirzepatide remains the only dual GIP/GLP-1 agent FDA-approved for weight management.
Zepbound is a once-weekly subcutaneous injection given in the abdomen, thigh, or upper arm. Dosing starts at 2.5mg and titrates upward through 5mg, 7.5mg, 10mg, 12.5mg, and 15mg, with a minimum of 4 weeks at each dose before advancing. Many patients reach a well-tolerated, effective dose at 10 or 12.5mg and never need to escalate to 15mg. In the pivotal SURMOUNT-1 trial, clinical trials showed average body-weight reduction of roughly 20.9% at the 15mg dose over 72 weeks in adults with obesity who did not have type 2 diabetes. Individual results vary, and rapid loss is not a goal of treatment; we aim for sustained, gradual reduction alongside protection of lean body mass.
Our approach is thorough and honest. We evaluate you medically before prescribing, screen for contraindications (including personal and family history of medullary thyroid cancer and MEN 2), review other medications, and order baseline labs when indicated. We also talk frankly about what Zepbound does not do: it is not a one-time fix, weight regain is common after discontinuation, and results are best when medication is paired with protein-forward nutrition, strength training, and adequate sleep. If tirzepatide is not the right fit, we can discuss Wegovy (semaglutide) or return to the broader medical weight loss program.
Who Qualifies
Who is a candidate for Zepbound?
Zepbound has two FDA-approved indications, but the conversation with a prescriber often covers more nuance than the label alone. Below are the patient profiles we most commonly see. You do not need all of the criteria to ask whether tirzepatide is a reasonable option for you.
BMI 30 or higher
FDA-approved indication for chronic weight management in adults with a body mass index of 30 kg/m² or higher, with no required comorbidity. This is the primary on-label use.
BMI 27+ with a comorbidity
Also on-label at BMI 27 or higher when paired with at least one weight-related condition: hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, or obstructive sleep apnea.
Type 2 diabetes
Tirzepatide is also marketed as Mounjaro for type 2 diabetes. For patients with T2DM and excess weight, the dual GIP/GLP-1 mechanism improves both glycemic control and body weight. Many patients are able to reduce other diabetes medications over time.
Obstructive sleep apnea with obesity
Zepbound is the only FDA-approved weight-loss medication with an OSA indication (December 2024). Approved for moderate-to-severe OSA in adults with obesity based on reductions in apnea-hypopnea index in the SURMOUNT-OSA trial. Does not replace CPAP therapy.
Failed prior lifestyle attempts
Patients who have done the work -- structured diet, exercise, behavior change -- without adequate sustained loss are appropriate candidates. Obesity is a chronic, relapsing condition, not a willpower problem.
Metabolic syndrome
Central adiposity, insulin resistance, elevated triglycerides, low HDL, and hypertension cluster together and respond well to incretin-based therapy. Improvements in blood pressure, lipids, and HbA1c are common alongside weight loss.
Plateau on semaglutide
Patients who have reached maximum-dose Wegovy (2.4mg) and plateaued, or whose tolerability is poor on semaglutide, frequently respond to a switch to tirzepatide. The top of the Zepbound dose range (15mg) also offers more headroom for patients who need higher potency. See our guide to the GLP-1 weight loss stall for what we evaluate before making changes.
Need for higher max-dose potency
For patients whose clinical targets (weight, HbA1c, sleep apnea severity) require stronger appetite and glycemic effect, the 12.5mg and 15mg tirzepatide doses provide more room to titrate than semaglutide's 2.4mg ceiling.
Zepbound vs Wegovy
Tirzepatide vs semaglutide, straightforwardly.
Both Zepbound (tirzepatide) and Wegovy (semaglutide) are FDA-approved once-weekly injections for chronic weight management. They work similarly, but they are not identical. Here is an honest, mechanism-based comparison. Our full Wegovy page is here.
| Zepbound (tirzepatide) | Wegovy (semaglutide) | |
|---|---|---|
| Mechanism | Dual agonist: GIP + GLP-1 | Single agonist: GLP-1 only |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Injection | Once weekly, subcutaneous | Once weekly, subcutaneous |
| Dose range | 2.5mg to 15mg | 0.25mg to 2.4mg |
| Avg weight loss (pivotal trial) | ~20.9% at 15mg, 72 weeks (SURMOUNT-1) | ~14.9% at 2.4mg, 68 weeks (STEP-1) |
| FDA weight approval | November 2023 | June 2021 |
| FDA OSA approval | Yes (December 2024) | No |
| Cardiovascular benefit claim | Not yet added to label | Yes (SELECT trial, 2024 label update) |
| Side-effect profile | Primarily GI (nausea, diarrhea, constipation); boxed thyroid warning | Primarily GI (nausea, diarrhea, constipation); boxed thyroid warning |
| Approx. cash price | $1,000 to $1,300 per month | $1,350 per month list |
How to read this. SURMOUNT-1 and STEP-1 were separate trials with different populations, so the weight-loss numbers are not a direct head-to-head. The SURPASS-2 trial directly compared tirzepatide to semaglutide 1mg in type 2 diabetes and favored tirzepatide on glycemic and weight endpoints, which is the strongest head-to-head evidence available. Wegovy uniquely carries an FDA label claim for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight. Zepbound uniquely carries an FDA label indication for moderate-to-severe OSA in adults with obesity. The right choice depends on your specific goals, medical history, tolerability, and coverage.
How It Works
How the Zepbound program works here.
Initial evaluation ($60)
A focused visit covering your weight history, medical and surgical history, medications, labs, family history (including thyroid cancer and MEN 2), and goals. If you do not have recent labs, we order a comprehensive metabolic panel, HbA1c, lipid panel, TSH, and CBC. Telehealth across 16 states or in person in Papillion.
Prescription & titration
If Zepbound is appropriate, we write a prescription to your preferred pharmacy (retail or specialty). We start at 2.5mg once weekly for a minimum of 4 weeks and titrate stepwise based on tolerance and response. You inject once per week, any day, any time of day.
Follow-up & refills ($60)
Follow-up visits at 4-week intervals through titration, then every 1 to 3 months for maintenance. At each refill visit we review weight, side effects, labs if due, and whether to adjust the dose. Direct access to your clinician between visits through the secure patient portal.
Cost & Coverage
Transparent pricing. Medication billed separately.
Our Visit Fee
- Flat $60 for initial Zepbound evaluation.
- Flat $60 per refill visit; no subscription.
- Covers evaluation, prescribing, and one month of messaging.
- Labs billed separately by your lab (usually through insurance).
Zepbound Medication
- Cash price: approximately $1,000 to $1,300 per month.
- Eli Lilly savings card may reduce out-of-pocket for commercial insurance holders.
- LillyDirect self-pay vial option may be available.
- Insurance coverage for weight-loss indication is inconsistent.
Insurance coverage for Zepbound. Commercial plans vary widely. Some cover Zepbound for BMI 30+ or BMI 27+ with comorbidity after prior authorization; others exclude anti-obesity medications entirely. Medicare does not currently cover Zepbound for weight loss. Coverage for the OSA indication is evolving. We will help you check your plan's formulary and can submit prior-authorization requests when appropriate. Patients without coverage may consider the manufacturer savings card or LillyDirect self-pay.
Important Safety Information
Risks, warnings, and contraindications.
Zepbound (tirzepatide) is a prescription medication with meaningful risks. This information is a summary and does not replace the FDA-approved prescribing information, which we will review with you at your visit. Full prescribing information, including the medication guide, is available from Eli Lilly.
Contraindications. Do not use Zepbound if you have:
- A personal or family history of medullary thyroid carcinoma (MTC).
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known serious hypersensitivity to tirzepatide or any excipient in Zepbound.
- Severe gastrointestinal disease (relative contraindication; includes gastroparesis).
Serious warnings and precautions.
- Pancreatitis. Acute pancreatitis has been reported with GLP-1 receptor agonists. Discontinue if suspected; do not restart if confirmed.
- Gallbladder disease. Cholelithiasis and cholecystitis have been reported, particularly with rapid weight loss.
- Hypoglycemia. Risk is increased when Zepbound is combined with insulin or sulfonylureas; these background agents may need dose reduction.
- Diabetic retinopathy complications. In patients with type 2 diabetes and pre-existing diabetic retinopathy, rapid improvement in glucose control may transiently worsen retinopathy.
- Acute kidney injury. Volume depletion from persistent GI side effects (vomiting, diarrhea) can precipitate AKI; hydration is essential.
- Severe hypersensitivity. Anaphylaxis and angioedema have been reported; discontinue immediately if suspected.
- Suicidal ideation and behavior. A 2024 class-label update prompted ongoing monitoring; we screen for mood and suicidal ideation and advise patients to report any changes.
- Pulmonary aspiration during anesthesia. Because tirzepatide delays gastric emptying, residual stomach contents may be present despite fasting. Inform your anesthesiologist and surgeon, and follow current pre-procedural guidance (often including holding the dose for one week or more before elective procedures).
Common side effects. In clinical trials, the most common adverse reactions (occurring in 5% or more of patients) were nausea (29%), diarrhea (23%), vomiting, constipation, abdominal pain, dyspepsia, fatigue, injection-site reactions, and hypersensitivity reactions. Most GI effects are mild to moderate, dose-dependent, and improve with slower titration.
Pregnancy. Discontinue Zepbound at least 2 months before a planned pregnancy. Effective contraception is recommended during treatment and for 2 months after stopping; tirzepatide may reduce the effectiveness of oral hormonal contraceptives, particularly during dose escalation. Under the FDA's current narrative labeling, traditional pregnancy categories (A/B/C/D/X) no longer apply.
Breastfeeding. Use while breastfeeding is not recommended. Risks to a nursing infant are not established.
Drug interactions. Because tirzepatide slows gastric emptying, it may affect absorption of oral medications. Coadministration with insulin or sulfonylureas raises hypoglycemia risk. Discuss all medications, including over-the-counter and supplements, at your visit.
This is not a complete list of warnings. Call 531-217-5257 or report adverse events to FDA MedWatch at 1-800-FDA-1088.
Serving the Omaha metro and 16 states.
Our physical office is in Papillion, Nebraska. We see Omaha-area patients in person and prescribe Zepbound via secure telehealth across the 16 states where our clinician is licensed. The greater Omaha metro carries some of the Midwest's higher rates of adult obesity, type 2 diabetes, and obstructive sleep apnea, and Zepbound is one tool for patients ready to address metabolic health with evidence-based medicine.
Telehealth across 16 states: Nebraska, Iowa, Kansas, Colorado, Arizona, Illinois, Utah, Idaho, New Mexico, Kentucky, Montana, North Dakota, South Dakota, Vermont, New Hampshire, and Maine. Zepbound prescriptions are written to your preferred pharmacy in-state.
FAQ
Zepbound questions we hear most.
Is Zepbound better than Wegovy?
In separate clinical trials, Zepbound (tirzepatide) has shown numerically higher average weight loss than Wegovy (semaglutide): SURMOUNT-1 reported about 20.9% average body-weight reduction at the 15mg tirzepatide dose over 72 weeks, versus about 14.9% for semaglutide 2.4mg in STEP-1. The only true head-to-head trial, SURPASS-2 in type 2 diabetes, favored tirzepatide on glycemic and weight endpoints. "Better" depends on your goals: Wegovy has an FDA cardiovascular risk-reduction indication that Zepbound does not; Zepbound has an OSA indication that Wegovy does not. Individual tolerability, insurance coverage, and cost also matter.
Does insurance cover Zepbound?
Coverage varies dramatically. Many commercial plans exclude anti-obesity medications; others cover Zepbound with prior authorization documenting BMI and prior lifestyle attempts. Medicare does not currently cover Zepbound for weight loss (coverage for the OSA indication is evolving). We help you check your plan's formulary and submit prior-authorization requests where appropriate. If your plan does not cover it, we discuss the Eli Lilly savings card and LillyDirect self-pay vial.
Can Zepbound treat sleep apnea?
Yes. In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial. Zepbound is the first and only weight-loss medication with an FDA OSA indication. It is not a replacement for CPAP therapy, but it can be used alongside CPAP and, for some patients, reduces the severity of OSA to the point that CPAP needs are re-evaluated by their sleep specialist.
What is the highest dose of Zepbound?
15mg once weekly is the maximum maintenance dose. Titration is stepwise through 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg, with at least 4 weeks at each step. Many patients reach an effective, well-tolerated dose at 10 or 12.5mg and never escalate to 15mg. For reference, Wegovy's maximum is 2.4mg weekly; Zepbound gives more headroom at the top end.
How fast do I lose weight on Zepbound?
Typically, a few pounds in the first 4 weeks on the 2.5mg starter dose, with more meaningful loss after titrating to 5mg and beyond. In SURMOUNT-1, loss continued through the full 72-week study. Expect a gradual, sustained trajectory, not rapid loss. Rapid loss increases risk of lean-muscle loss, gallstones, and relapse; gradual is the goal. Pair Zepbound with protein-forward nutrition and resistance training for the best results.
Can I switch from Wegovy to Zepbound?
Yes. This is a common request from patients who plateau at Wegovy 2.4mg, have intolerable side effects, or experience coverage changes. We typically start tirzepatide at 2.5mg or 5mg rather than matching semaglutide dose-for-dose, because the drugs differ in potency and mechanism. There is a short re-titration period before you reach your maintenance dose.
Can Zepbound cause thyroid cancer?
Zepbound carries an FDA boxed warning for thyroid C-cell tumors based on rodent studies. Whether this risk translates to humans is unknown. Medullary thyroid carcinoma is very rare. Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2, and we screen for these at intake. This warning is a class effect shared with semaglutide (Wegovy, Ozempic).
Can I get Zepbound by telehealth in Nebraska?
Yes. Zepbound is prescribed by secure telehealth to patients physically located in any of the 16 states where our clinician is licensed, including Nebraska. In-person visits are available at our Papillion office. Expect baseline labs and a thorough medical review before a first prescription is written. The prescription is sent to the pharmacy of your choice.
Ready to ask whether Zepbound is right for you?
$60 initial visit, $60 per refill, no subscription. Medication billed separately through your pharmacy. In-person in Papillion or telehealth across 16 states.
Book an Appointment